

Ethan J Rowin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4288387/publications.pdf>

Version: 2024-02-01

141
papers

5,863
citations

71061

41
h-index

79644

73
g-index

144
all docs

144
docs citations

144
times ranked

4204
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2014, 130, 484-495.	1.6	783
2	Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1915-1928.	1.2	257
3	Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. <i>Journal of the American College of Cardiology</i> , 2017, 69, 761-773.	1.2	252
4	Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2019, 4, 644.	3.0	222
5	Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥ 60 Years of Age. <i>Circulation</i> , 2013, 127, 585-593.	1.6	200
6	How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. <i>JAMA Cardiology</i> , 2016, 1, 98.	3.0	191
7	Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2017, 136, 2420-2436.	1.6	183
8	Diagnosis and Evaluation of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 372-389.	1.2	152
9	Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 116, 757-764.	0.7	148
10	Low Operative Mortality Achieved With Surgical Septal Myectomy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1307-1308.	1.2	146
11	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1399-1409.	1.2	142
12	Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 441-447.	1.3	138
13	Left Ventricular Unloading Before Reperfusion Promotes Functional Recovery After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 501-514.	1.2	138
14	Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. <i>Circulation</i> , 2016, 133, 62-73.	1.6	135
15	Management of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 390-414.	1.2	129
16	Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018, 6, 353-363.	1.9	105
17	Significance of False Negative Electrocardiograms in Preparticipation Screening of Athletes for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2012, 110, 1027-1032.	0.7	92
18	Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3033-3043.	1.2	82

#	ARTICLE	IF	CITATIONS
19	Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1659-1669.	2.3	80
20	Global Burden of Hypertrophic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018, 6, 376-378.	1.9	77
21	Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. <i>Annals of Cardiothoracic Surgery</i> , 2017, 6, 353-363.	0.6	75
22	Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2014, 7, 967-975.	1.6	71
23	Role of Exercise Testing in Hypertrophic Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1374-1386.	2.3	68
24	Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	63
25	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 116, 436-441.	0.7	62
26	Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2706-2713.	1.0	61
27	Three-dimensional Deep Convolutional Neural Networks for Automated Myocardial Scar Quantification in Hypertrophic Cardiomyopathy: A Multicenter Multivendor Study. <i>Radiology</i> , 2020, 294, 52-60.	3.6	58
28	CMR With Late Gadolinium Enhancement in Genotype Positive Phenotype Negative Hypertrophic Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 119-122.	2.3	55
29	Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	54
30	Papillary Muscle Insertion Directly into the Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy, Its Identification and Cause of Outflow Obstruction by Cardiac Magnetic Resonance Imaging, and Its Surgical Management. <i>American Journal of Cardiology</i> , 2013, 111, 1677-1679.	0.7	53
31	Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. <i>Nature Communications</i> , 2021, 12, 873.	5.8	53
32	The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 197.	1.3	50
33	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005820.	2.1	50
34	How to Image Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	49
35	Why we need more septal myectomy surgeons: An emerging recognition. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1681-1685.	0.4	48
36	Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2019, 125, 370-378.	2.0	47

#	ARTICLE	IF	CITATIONS
37	What Do Patients With Hypertrophic Cardiomyopathy Die from?. American Journal of Cardiology, 2016, 117, 434-435.	0.7	46
38	Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 120, 2256-2264.	0.7	45
39	Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1647-1655.	1.2	45
40	Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm, 2021, 18, 1012-1023.	0.3	44
41	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, e003689.	1.6	43
42	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation, 2019, 139, 830-833.	1.6	43
43	The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging. JACC: Cardiovascular Imaging, 2020, 13, 2002-2016.	2.3	42
44	Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 121, 986-996.	0.7	41
45	Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 947-958.	2.3	41
46	Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circulation: Cardiovascular Interventions, 2019, 12, e007673.	1.4	39
47	Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. Journal of Cardiovascular Electrophysiology, 2017, 28, 531-537.	0.8	38
48	Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation, 2017, 135, 2317-2319.	1.6	35
49	Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. American Journal of Medicine, 2018, 131, e235-e239.	0.6	35
50	Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 1862-1865.	0.7	34
51	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (^β -Myosin Heavy) Tj ETQq1 1 0.784314 rgBT Cardiovascular Imaging, 2017, 10, .	1.3	31
52	Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Circulation, 2018, 137, 1973-1975.	1.6	31
53	Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. American Journal of Medicine, 2018, 131, 200.e1-200.e8.	0.6	31
54	Velocity Vector Imaging in the Measurement of Left Ventricular Myocardial Mechanics on Cardiac Magnetic Resonance Imaging: Correlations with Echocardiographically Derived Strain Values. Journal of the American Society of Echocardiography, 2013, 26, 1153-1162.	1.2	29

#	ARTICLE	IF	CITATIONS
55	Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1409-1420.	0.7	28
56	Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2020, 125, 120-126.	0.7	27
57	Return to Play for Athletes After COVID-19 Infection. <i>JAMA Cardiology</i> , 2021, 6, 997.	3.0	25
58	Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019, 123, 1859-1862.	0.7	24
59	Left Ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 1031-1033.	0.5	22
60	Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008123.	2.1	21
61	Improved Quantification of Myocardium Scar in Late Gadolinium Enhancement Images: Deep Learning Based Image Fusion Approach. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 303-312.	1.9	20
62	Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2021, 332, 127-132.	0.8	20
63	Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2020, 128, 75-83.	0.7	19
64	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now. <i>American Journal of Medicine</i> , 2017, 130, 119-123.	0.6	17
65	Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. <i>American Journal of Cardiology</i> , 2020, 127, 139-141.	0.7	16
66	Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019, 124, 113-121.	0.7	15
67	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1821-1831.	0.8	15
68	Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data Evolve. <i>JAMA Cardiology</i> , 2021, 6, 136.	3.0	14
69	Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2021, 151, 86-92.	0.7	14
70	Hypertrophic Cardiomyopathy: New Concepts and Therapies. <i>Annual Review of Medicine</i> , 2022, 73, 363-375.	5.0	14
71	Plasma Proteomic Profiling in Hypertrophic Cardiomyopathy Patients before and after Surgical Myectomy Reveals Post-Procedural Reduction in Systemic Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2474.	1.8	13
72	Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009796.	2.1	13

#	ARTICLE	IF	CITATIONS
73	Asymptomatic Young Man with Danon Disease. <i>Texas Heart Institute Journal</i> , 2014, 41, 332-334.	0.1	12
74	Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 647857.	1.1	11
75	Outcomes Over Follow-up 10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, 163, 91-97.	0.7	11
76	Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. <i>Heart Rhythm</i> , 2022, 19, 782-789.	0.3	11
77	Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2018, 30, 125-128.	0.4	10
78	Intraoperative Provocative Testing in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 182-190.	1.2	10
79	Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. <i>American Journal of Cardiology</i> , 2020, 127, 135-138.	0.7	10
80	Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. <i>Scientific Reports</i> , 2022, 12, 5211.	1.6	10
81	What Causes Hypertrophic Cardiomyopathy?. <i>American Journal of Cardiology</i> , 2022, 179, 74-82.	0.7	10
82	Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy. <i>Echocardiography</i> , 2017, 34, 1247-1249.	0.3	9
83	Coronary Embolization in Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. <i>American Journal of Cardiology</i> , 2015, 115, 1318-1319.	0.7	8
84	Thinking Outside the Heart to Treat Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e016260.	1.6	7
85	Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 131-133.	1.3	6
86	Hypertrophic Cardiomyopathy: Is a "Cure" Coming . . . Or Is It Already Here?. <i>American Journal of Medicine</i> , 2020, 133, 886-888.	0.6	6
87	Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. <i>Heart Rhythm</i> , 2021, 18, 148-150.	0.3	6
88	Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. <i>Journal of Animal Science and Technology</i> , 2015, 2, E1-E7.	0.8	6
89	Impact of Comorbidities on Atrial Fibrillation and Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, , .	0.8	6
90	Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2022, 11, e024566.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. <i>American Journal of Medicine</i> , 2022, 135, 1244-1246.	0.6	6
92	Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, 179, 70-73.	0.7	6
93	Adipositas Cordis. <i>Circulation</i> , 2010, 122, 2212-2214.	1.6	5
94	Hypertrophic Cardiomyopathy in "Real-World" Community Cardiology Practice. <i>American Journal of Cardiology</i> , 2020, 125, 1398-1403.	0.7	5
95	Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. <i>American Journal of Cardiology</i> , 2021, 147, 145-146.	0.7	5
96	Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based) <i>Tj ETQq0 0,0 rgBT /Qverlock 10</i>	0.7	5
97	Cardiovascular Diseases That Have Emerged From the Darkness. <i>Journal of the American Heart Association</i> , 2021, 10, e021095.	1.6	5
98	Evidence for Left Ventricular Outflow Tract Obstruction With Minimal Septal Hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003588.	1.3	4
99	The ESC Risk Score Is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1626-1628.	0.8	4
100	Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2020, 125, 1896-1900.	0.7	4
101	Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. <i>American Journal of Cardiology</i> , 2021, 142, 130-135.	0.7	4
102	Evaluating Histopathology to Improve Our Understanding of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2171-2173.	1.2	4
103	Anatomic validation of late gadolinium enhancement as evidence of myocardial scarring in LAMP2 cardiomyopathy. <i>European Heart Journal</i> , 2017, 38, 2444-2444.	1.0	3
104	Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)" <i>Circulation</i> , 2019, 139, 1557-1558.	1.6	3
105	Cardiac Sarcoidosis Mimicking Hypertrophic Cardiomyopathy. <i>JACC: Case Reports</i> , 2020, 2, 2060-2062.	0.3	3
106	Myocardial Bridge or Something Else?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 332-337.	0.6	3
107	What is the best imaging test for patients with hypertrophic cardiomyopathy? It depends on the clinical question!. <i>Journal of Cardiovascular Computed Tomography</i> , 2014, 8, 438-441.	0.7	2
108	Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. <i>American Journal of Medicine</i> , 2017, 130, 1236-1237.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy". <i>Circulation</i> , 2018, 137, 2541-2542.	1.6	2
110	Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy. <i>Heart</i> , 2019, 105, 1850-1851.	1.2	2
111	Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2019, 25, 690-692.	0.7	2
112	Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1351-1352.	0.5	2
113	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1913.	1.2	2
114	Fixed, high-volume alcohol dose for septal ablation: High risk with no benefit. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 1219-1220.	0.7	2
115	Combined alcohol septal ablation and transcatheter aortic valve replacement: Drunk and playing with fire. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 838-839.	0.7	2
116	Concerns About the HCM Risk-Kids Study. <i>JAMA Cardiology</i> , 2020, 5, 362.	3.0	2
117	After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature?. <i>American Journal of Cardiology</i> , 2021, 142, 136-137.	0.7	2
118	Standards for writing Society for Cardiovascular Magnetic Resonance (SCMR) endorsed guidelines, expert consensus, and recommendations: a report of the publications committee. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 129.	1.6	2
119	Transcatheter Mitral Intervention Relieves Dynamic Outflow Obstruction and Reduces Cardiac Workload in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009171.	1.6	2
120	Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. <i>American Journal of Cardiology</i> , 2022, 174, 120-125.	0.7	2
121	Response to Letter Regarding Article, "Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy". <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, .	1.3	1
122	A Case of Multiple Ventricular Gradients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1829-1832.	0.6	1
123	Editorial commentary: Role of cardiac magnetic resonance imaging in the evaluation of amyloidosis. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 95-96.	2.3	1
124	Two Tales of Cardiomyopathy: Underscore for One Health Initiative. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2811-2814.	0.6	1
125	Abstract 17402: Single Nuclei RNA-sequencing of Human Hypertrophic Cardiomyopathy Myectomy Samples Reveals Common Novel Mechanisms of Pathogenesis and Potential Therapeutic Targets Regardless of Genotype. <i>Circulation</i> , 2020, 142, .	1.6	1
126	Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). <i>American Journal of Cardiology</i> , 2022, 168, 163-165.	0.7	1

#	ARTICLE	IF	CITATIONS
127	Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. American Journal of Cardiology, 2022, , .	0.7	1
128	Global Dissemination and Implementation of Contemporary Management Principles for Hypertrophic Cardiomyopathy and Role of the International HCM Summit. American Journal of Cardiology, 2022, 172, 146-149.	0.7	1
129	Abstract 12214: Characterization of Iatrogenic Left Bundle Branch Block After Septal Myectomy for Hypertrophic Cardiomyopathy. Circulation, 2021, 144, .	1.6	1
130	Reply. JACC: Heart Failure, 2018, 6, 807-808.	1.9	0
131	Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy?. Trends in Cardiovascular Medicine, 2021, 31, 32-33.	2.3	0
132	Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2020, , 101-102.		0
133	Abstract 15961: Multicenter Prospective Prevention of Sudden Death in High Risk Patients Utilizing Enhanced ACC/AHA Risk Model. Circulation, 2020, 142, .	1.6	0
134	Abstract 15889: The Role of Physical Deconditioning in Distinguishing Hypertrophic Cardiomyopathy From Athlete's Heart. Circulation, 2020, 142, .	1.6	0
135	Abstract 17341: Obesity is Associated With Progressive Heart Failure in Hypertrophic Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
136	Abstract 16082: Machine Learning to Improve Left Ventricular Scar Quantification in Hypertrophic Cardiomyopathy Patients. Circulation, 2020, 142, .	1.6	0
137	Congenital Left Ventricular Diverticulum Complicated by Cardioembolic Stroke. Case, 2022, 6, 55-58.	0.1	0
138	Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten?. Asian Cardiovascular and Thoracic Annals, 2022, , 021849232210744.	0.2	0
139	Winter Is Coming. JACC: Case Reports, 2022, 4, 99-101.	0.3	0
140	Abstract 9755: Impact of Outflow Obstruction and Septal Myectomy on Long Term Risk of New Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2021, 144, .	1.6	0
141	Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States. Journal of Clinical Medicine, 2022, 11, 3898.	1.0	0